Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.

Jerome Fortin,Ruxiao Tian,Ida Zarrabi,Graham Hill,Eleanor Williams,Gonzalo Sanchez-Duffhues,Midory Thorikay,Parameswaran Ramachandran,Robert Siddaway,Jong Fu Wong,Annette Wu,Lorraine N. Apuzzo,Jillian Haight,Annick You-Ten,Bryan E. Snow,Andrew Wakeham,David J. Goldhamer,Daniel Schramek,Alex N. Bullock,Peter ten Dijke,Cynthia Hawkins,Tak W. Mak

DOI: https://doi.org/10.1016/j.ccell.2020.02.002

IF: 50.3

2020-01-01

Cancer Cell

Abstract:Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors for which there is currently no effective treatment. Some of these tumors combine gain-of-function mutations in ACVR1, PIK3CA, and his- tone H3-encoding genes. The oncogenic mechanisms of action of ACVR1 mutations are currently unknown. Using mouse models, we demonstrate that Acvr1(G328v) arrests the differentiation of oligodendroglial lineage cells, and cooperates with Hist1h3b(K27)(M) and Pik3ca(H1047R) to generate high-grade diffuse gliomas. Mechanistically, Acvr1(G328v) upregulates transcription factors which control differentiation and DIPG cell fitness. Furthermore, we characterize E6201 as a dual inhibitor of ACVR1 and MEK1/2, and demonstrate its efficacy toward tumor cells in vivo. Collectively, our results describe an oncogenic mechanism of action for ACVR1 mutations, and suggest therapeutic strategies for DIPGs.